Browsing Tag
Amgen Inc.
5 posts
Why BeOne Medicines (ONC) just strengthened its China oncology play with Imdelltra approval
BeOne Medicines wins China approval for Amgen’s Imdelltra in lung cancer. Read why this matters for ONC, competition, and China oncology growth.
Amgen (NASDAQ: AMGN) wins EC approval for UPLIZNA in generalized myasthenia gravis market
European Commission clears Amgen Inc.’s UPLIZNA for generalized myasthenia gravis. Discover what this means for competition, pricing, and the autoimmune drug market.
Amgen (NASDAQ: AMGN) bets on protein degradation with Dark Blue Therapeutics acquisition
Amgen acquires Dark Blue Therapeutics for up to $840M, expanding into MLLT1/3-targeted AML therapies. Find out what this means for oncology innovation today.
Amgen’s landmark Repatha trial to take center stage at AHA 2025 with major cardiovascular prevention results
Find out how Amgen’s Repatha phase 3 trial is redefining cardiovascular prevention and reshaping investor sentiment at AHA 2025.
Pfizer just flipped the script on drug prices—now Eli Lilly and Amgen are ripping. Is this the start of a new pharma bull run?
Pfizer’s U.S. drug-pricing pact triggers a pharma relief rally. See what it means for Eli Lilly, Amgen, and investors today—read the data-driven outlook.